Stocks · News reference
IMUNON Enters Into CRADA With National Cancer Institute To Advance DNA-Based IL‑12 Immunotherapy IMNN‑001
Collaboration with NCI's Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001in new indications and combination regimensIMUNON retains ownership of its background intellectual property with an opportunity
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Imunon, Inc. (IMNN)
Filed: 2026-09-29 AccNo: 0001493152-26-044792 Size: 383 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits
IMUNON Reports Overall Survival Results, Advances Phase 3 OVATION 3 Trial
2026 R&D Day presentation highlights include:Review of final Randomized Phase 2 overall survival resultsSupportive Preliminary MRD Study Data and translational findingsPathway to confirmatory readout in OVATION
IMUNON Says Independent Monitoring Committee Recommends Continuing IMNN-001 Phase 2 Study Without Modification
Independent Data Monitoring Committee recommends the ongoing Phase 2 MRD study continue without modification following its review of all safety data to dateNo cytokine release syndrome, systemic toxicities or serious